Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

N/A

3(37.5%)

Phase 1

3(37.5%)

Phase 4

1(12.5%)

Early Phase 1

1(12.5%)

8Total

N/A(3)

Phase 1(3)

Phase 4(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04082858Phase 1Terminated

Ketamine Interleaved With Electroconvulsive Therapy for Depression

Role: lead

NCT02414932Early Phase 1Completed

Ketamine for Depression Relapse Prevention Following ECT

Role: lead

NCT03256162Phase 1Completed

Ketamine as an Adjunctive Therapy for Major Depression

Role: lead

NCT02661061Phase 1Terminated

Ketamine for Relapse Prevention in Recurrent Depressive Disorder

Role: lead

NCT01907217Phase 4Completed

Enhancing the Effectiveness of Electroconvulsive Therapy in Severe Depression

Role: lead

NCT03396887Not ApplicableUnknown

The Effectiveness of a Smartphone Application in the Treatment of Alcohol Use Disorder

Role: lead

NCT02404662Not ApplicableUnknown

Trial of Supportive Text Messages for Patients With Alcohol Use Disorder and a Co-morbid Depression

Role: lead

NCT01037868Not ApplicableCompleted

Usefulness of Supportive Text Messages in the Treatment of Depressed Alcoholics

Role: collaborator

All 8 trials loaded